The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Neuroendocrine Carcinoma Market From 2026 To 2030?
The neuroendocrine carcinoma market has demonstrated substantial growth in recent years. This market is projected to expand from $1.75 billion in 2025 to $1.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The expansion observed in the historic period was driven by factors such as the rising prevalence of neuroendocrine carcinoma, increased application of imaging for early detection, the early adoption of surgical tumor removal, the development of initial chemotherapy protocols, and growing clinical awareness of nec subtypes.
The neuroendocrine carcinoma market size is anticipated to demonstrate robust growth over the next few years. It is expected to grow to $2.47 billion in 2030, achieving a compound annual growth rate (CAGR) of 7.1%. This projected expansion during the forecast period can be attributed to the wider application of targeted biologic therapies, increased investment in immunotherapy research, improved availability of precision diagnostic tools, the development of advanced radiotherapy systems, and the rising adoption of multidisciplinary oncology centers.
Significant trends in the forecast period include the increasing adoption of chemotherapy for managing aggressive tumors, a greater use of targeted therapies in advanced neuroendocrine carcinoma cases, the growing utilization of radiotherapy for localized tumor control, an expansion of biopsy and serology-based diagnostic approaches, and an escalating demand for multidisciplinary treatment planning.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
Which Key Factors Are Driving The Neuroendocrine Carcinoma Market Growth?
The neuroendocrine carcinoma market is expected to experience growth propelled by the increasing prevalence of targeted therapies. These treatments are specifically designed to accurately target and disrupt the molecular processes or genetic alterations that contribute to a disease, especially cancer. The demand for targeted therapies is rising due to their precision in addressing specific genetic mutations, advancements in personalized medicine, and the provision of better patient outcomes with fewer side effects. For neuroendocrine carcinoma, the development of targeted therapies allows for specific intervention against the tumor’s genetic and biochemical profiles, leading to enhanced treatment precision and effectiveness. For instance, in July 2023, a report jointly published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, revealed that while there were 247 gene therapies in Phase II at the end of Q1 2023, this figure saw a 5% increase, reaching 260 by the close of Q2. Therefore, the expansion of targeted therapies is a significant impetus for the growth of the neuroendocrine carcinoma market.
How Are Segments Identified Within The Neuroendocrine Carcinoma Market Segment Framework?
The neuroendocrine carcinoma market covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging, Biopsy, Serology
3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Which Trends Are Guiding The Direction Of The Neuroendocrine Carcinoma Market?
Major companies within the neuroendocrine carcinoma market are increasingly focusing on developing advanced therapies, such as targeted radiopharmaceutical therapy, to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy utilizes radioactive molecules engineered to specifically target and deliver radiation to cancer cells, thereby minimizing harm to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received orphan drug designation from the Food and Drug Administration (FDA) for ABD-147, intended for the treatment of neuroendocrine carcinoma. This therapeutic agent is designed to selectively target tumors expressing the DLL3 protein, which is commonly overexpressed in aggressive neuroendocrine cancers like small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The designation offers substantial development advantages, including tax credits for clinical trials and the potential for market exclusivity, positioning ABD-147 as a promising treatment in this specialized oncology area.
Who Are The Companies Competing Within The Neuroendocrine Carcinoma Market?
Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
Get The Full Neuroendocrine Carcinoma Market Report:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
Which Region Accounts For The Largest Portion Of The Neuroendocrine Carcinoma Market?
North America was the largest region in the neuroendocrine carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neuroendocrine Carcinoma Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
Browse Through More Reports Similar to the Global Neuroendocrine Carcinoma Market 2026, By The Business Research Company
Nephrologists Market Report 2026
Nephrologists Market Report 2020 2030 Covid 19 Implications And Growth
Clinical Diagnostics Market Report
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model